MannKind Slides on Second Afrezza Complete Response

It was just as MannKind Corp.'s bearish investors predicted when the FDA said it was extending the PDUFA date for inhaled insulin candidate Afrezza: The agency issued a complete response letter  the second  for use of the product in Type I and Type II diabetes.